Following on from information provided to NICE by the company in August 2009, the appraisal of Head and neck cancer - contusugene ladenovec [ID76] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 76 |
| Referral date | 01 March 2009 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | Jeremy Powell |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 November 2022 | Following on from information provided to NICE by the company in August 2009, the appraisal of Head and neck cancer - contusugene ladenovec [ID76] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 November 2022 | Discontinued. Following on from information provided to NICE by the company in August 2009, the appraisal of Head and neck cancer - contusugene ladenovec [ID76] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 14 August 2009 | Appraisal suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual